$16.03
+0.05 (+0.31%)
Open$15.89
Previous Close$15.98
Day High$16.24
Day Low$15.20
52W High$43.85
52W Low$7.15
Volume—
Avg Volume487.5K
Market Cap267.12M
P/E Ratio—
EPS$-17.32
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-42.5% upside
Current
$16.03
$16.03
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 204.80M | 178.43M | 26.00M |
| Net Income | -381,859,767 | -299,419,576 | 1.01M |
| Profit Margin | -186.5% | -177.1% | 3.9% |
| EBITDA | -301,840,137 | -249,824,124 | 1.64M |
| Free Cash Flow | — | — | 646.8K |
| Rev Growth | +14.8% | +14.8% | +22.0% |
| Debt/Equity | 4.05 | 4.05 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |